Nicotine & Tobacco in 2026
Combustible smoking is down. Vaping, pouches, and youth initiation are the new frontiers.
Body — 8 lenses: [Science: nicotinic acetylcholine receptor agonist; heterogeneous subtype effects. Biology: acute cardiovascular effects, chronic cardiovascular + cancer risk from combustion (not primarily nicotine), EVALI and vaping-associated lung injury history, nicotine-only harm profile. Psychology: rapid dependence, highest relapse rates of any SUD. Policy: FDA CTP, T21, flavor bans, SynZonic/Zyn scrutiny. Trends: youth vaping declining overall, pouches rising fast, combustibles at historic lows. Social: Big Tobacco’s documents legacy, truth® campaign. Treatment: FDA-approved — varenicline, bupropion, NRT (patch/gum/lozenge/inhaler/nasal spray). Harm reduction: step-down, combination NRT, vape-to-quit (controversial but supported by some evidence).]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionYouth & Young AdultsPeer-Reviewed Research
Continue reading
More from this section
The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.
Science & MedicineFrance Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.
France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.
Science & MedicineThe FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.
DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.